Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients
Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine
Recipient of the 2020-2021 Dr. Margaret Becklake Fellowship: Mikashmi Kohli
A postdoctoral fellow from the RI-MUHC is recognized for international work on TB diagnostics
Three COVID-19 projects at the RI-MUHC to receive CIHR funding
A $109M fund aims to mitigate impact of the pandemic on care delivery in Canada and beyond, as well as contribute to better understanding of the disease
COVID-19 pandemic: Looking back to better tackle future challenges
In two recent studies, RI-MUHC researchers provide useful information for evaluating public health strategies
Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper
A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis
COVID-19 pandemic: the need for privacy and digital contact tracing
RI-MUHC researcher Abhinav Sharma calls for an approach emphasizing voluntary consent
Innovation Moves Online for the 2020 McGill Clinical Innovation Competition
RI-MUHC research team, Emily McDonald and Todd C. Lee, ties for Marika Zelenka Roy Innovation Prize
Why do some non-smokers get COPD while many heavy smokers don’t?
A new study highlights a strong risk factor for COPD related to lung development
RI-MUHC trainee wins scholarship from the Société québécoise d’hypertension artérielle
Congratulations to Joseph Mussa!
Hydroxychloroquine not effective in preventing the development of COVID-19 when used as post-exposure prophylaxis
A new study suggests that hydroxychloroquine is not effective in preventing the development of COVID-19 in individuals exposed to SARS-CoV-2